As Head of Digital Health across all of Oncology R&D at AstraZeneca, 我的重点是利用新兴技术来改善患者护理和扩大肿瘤治疗的证据基础. 我在肿瘤药物开发和罕见疾病中跨肿瘤类型开发和实施创新的患者相关证据策略方面具有丰富的经验.

I believe that reliable empirical evidence is the backbone of empowered decision- making. I’m most passionate about measuring the impact of cancer, and the tolerability of anti-cancer therapies, on patients in a rigorous and reliable way. 这项工作在为患者提供做出重要医疗保健决定的最佳证据方面至关重要, such as treatment choice, following a cancer diagnosis.

As founder of the strategic advising group, Patient Relevant Evidence, 我的工作是为非营利倡导实体和学术联盟优化以患者为中心的证据生成. 这包括最近与欧洲癌症治疗组织的合作，重点是制定国际标准，分析患者报告的结果和癌症临床试验的生活质量终点，以进行监管评估.

Most recently, I led Roche/Genentech’s oncology patient-centred outcomes research group, 在此期间，我负责新的食品和药物管理局(FDA)患者报告的淋巴瘤和血友病产品的结果标签声明. Additionally, 我在罗氏开发了肺癌症状工具，该工具被纳入多个一线3期注册试验. Prior to that, 我曾担任辉瑞肿瘤公司健康经济学和结果研究主管，负责开发管道的结果研究策略.

Over the course of my career, I have been a contributor and advisor to numerous policy initiatives such as the landmark 21st Century Cures legislation. 我参加了各种FDA研讨会和关于药物开发中患者体验重要性的立法简报. 我还曾担任Critical Path Institute的非小细胞肺癌工作组的联合主席. My work has been recognised by Former Vice President Biden’s Cancer Moonshot Initiative.

我在康涅狄格大学医学院完成了公共卫生硕士学位，主修流行病学和结果研究. 

 

Digital health has the potential to reimagine healthcare. By quantifying the patient voice, we can strengthen decision-making across the product development lifecycle, 改善患者的整体体验，帮助患者在自己的护理中成为平等的合作伙伴.

Alicyn Campbell Head of Digital Health, Oncology R&D

CURRENT ROLE

Head of Digital Health, Oncology R&D

2019 – present

Founder at Patient Relevant Evidence, 有限责任公司服务于战略咨询角色，以优化非营利性倡导实体和学术联盟以患者为中心的证据生成

2019 – present

Scientific advisory board member at CareVive Systems Inc.

2012 – 2019

Served as Global Head, 基因泰克(Genentech)的肿瘤患者报告结果领导着一个由结果研究科学家组成的多元化团队，量化临床试验中患者的声音，更好地了解新疗法的影响

Featured publications

使用患者报告的结果来理解和衡量患者对新型细胞和基因疗法的体验.

L Lasiter, A Campbell, E Basch, S Hudgens, M Stewart, J Wu, A Leahy, J Allen. Ther Innov Regul Sci. 2020 June 22. Published online ahead of print 

http://pubmed.ncbi.nlm.nih.gov/32572771/

 

癌症随机对照试验中生活质量和患者报告结局终点分析的国际标准:SISAQOL联盟的建议

C Coens, M Pe, AC Dueck, J Sloan, E Basch, M Calvert, A Campbell, et al. Lancet Oncol. 2020 Feb. 21(2): e83-e96

http://pubmed.ncbi.nlm.nih.gov/32007209/

 

Improving Attribution of Adverse Events in Oncology Clinical Trials.

GC George, PC Barata, A Campbell, et al. Cancer Treatment Reviews. 2019 June. 76:33 – 40

http://doi.org/10.1016/j.ctrv.2019.04.004

 

不良事件通用术语标准的患者报告结果版本:行业资助的肿瘤临床试验项目选择方法.

PC Trask, AC Dueck, E Piault, A Campbell. Clin Trials. 2018 Dec. 15(6):616-623

http://pubmed.ncbi.nlm.nih.gov/30230365/

 

局部晚期和转移性乳腺癌随机对照试验中患者报告的结果数据的统计分析:一项系统综述.

M Pe, L Dorme, C Coens, E Basch, M Calvert, A Campbell, et al. Lancet Oncol. 2018 Sept. 19(9): e459-e469

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30418-2/fulltext

 

在癌症随机临床试验中对生活质量数据进行标准化分析.

A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, et al. Clin Trials. 2018 Dec. 15(6): 624-630

http://pubmed.ncbi.nlm.nih.gov/30141714/

 

分析癌症临床试验患者报告的结果和生活质量终点数据:制定国际标准的开端.

A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, et al. Lancet Oncol. 2016 Nov. 17(11): e510-e514

http://pubmed.ncbi.nlm.nih.gov/27769798/

 

非霍奇金淋巴瘤治疗满意度问卷的验证:评估利妥昔单抗从静脉注射到皮下注射的变化.

C Theodore-Oklota, L Humphrey, C Wiesner, G Schnetzler, S Hudgens, A Campbell. Patient Prefer Adherence. 2016 Sep 13. 10:1767-1776

http://pubmed.ncbi.nlm.nih.gov/27695295/

 

dacomitinib在韩国KRAS野生型晚期非小细胞肺癌患者化疗和厄洛替尼或吉非替尼难治的安全性和有效性:I/II期试验.

K Park, BC Cho, DW Kim, MJ Ahn, SY Lee, D Gernhardt, I Taylor, A Campbell, et al. J. Thorac Oncol. 2014 Oct. 9(10):1523-31

http://pubmed.ncbi.nlm.nih.gov/25521398/

 

AVAPERL中接受贝伐单抗或贝伐单抗+培美曲塞维持治疗的晚期非小细胞肺癌患者的健康相关生活质量.

A Rittmeyer, V Gorbunova, A Vikstrom, A Scherpereel, JO Kim, MJ Ahn, A Chella, C Chouaid, A Campbell, F Barlesi. J. Thorac Oncol. 2013 Nov. 8(100):1409-16

http://pubmed.ncbi.nlm.nih.gov/24077452/